CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies – OncLive
OncLive |
CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies
OncLive In addition to CAR T-cell therapies, checkpoint inhibition is also an area that investigators are focusing on in various lymphoma subtypes, said Younes, professor of medicine and chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center. |
